文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

蜂胶补充对COVID-19患者临床症状影响的随机对照试验方案结构化摘要

The effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19): A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-12-03

本研究为双盲、安慰剂对照、平行组、随机II期临床试验,旨在评估蜂胶补充对COVID-19患者临床症状的影响。计划招募80例经PCR确诊的18-75岁患者,干预组(N=40)接受含300 mg伊朗绿蜂胶提取物的片剂每日三次共2周,对照组(N=40)接受含300 mg微晶纤维素的安慰剂片剂每日三次共2周。主要结局为从基线至2周结束时COVID-19临床症状持续时间和严重程度的变化。

要点

  • 蜂胶组每日三次每次300 mg伊朗绿蜂胶提取物片剂,疗程2周。
  • 主要结局为2周内COVID-19临床症状持续时间和严重程度的变化。
  • 样本量80例,按1:1随机分组,按性别分层,区组大小为4。

核心结论

  • 该试验方案旨在评估蜂胶补充对COVID-19患者临床症状的影响,结果尚未报告。

研究设计与样本

  • 双盲、安慰剂对照、平行组、随机II期临床试验,计划总样本量80例,每组40例。

关键数值与推荐

  • 干预组接受含300 mg伊朗绿蜂胶提取物的片剂每日三次共2周。
  • 对照组接受含300 mg微晶纤维素的安慰剂片剂每日三次共2周。
  • 主要结局为从基线至2周结束时COVID-19临床症状持续时间和严重程度的变化。
  • 纳入标准为经PCR确诊的COVID-19患者,年龄18至75岁,无当前使用华法林或蜂胶补充剂史,无蜂产品过敏。
  • 随机化按1:1比例,区组大小为4,按性别分层,由试验药剂师使用随机数字表准备序列。

局限性

  • 试验注册为回顾性注册(2020年10月20日注册)。
  • 方案版本为1.0,2020年10月10日,招募预计2021年3月21日完成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to assess the effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19). TRIAL DESIGN: This is a Double-Blind, Placebo-Controlled, Parallel Arm, Randomized Phase ΙΙ Clinical Trial. PARTICIPANTS: Patients with the confirmed COVID-19 based on the PCR test are eligible to participate in the trial if they are 18 to 75 years of age and have no history of the current use of warfarin or propolis supplement and presence of sensitivity to bee products. Patients will be recruited from the Al-Zahra hospital in Isfahan city, Isfahan, Iran. INTERVENTION AND COMPARATOR: Participants (N=40) in the intervention group will receive an identical propolis tablet (containing 300 mg Iranian green propolis extract) three times a day for a period of 2 weeks. Participants (N=40) in the control group will receive an identical placebo tablet (containing 300 mg microcrystalline cellulose) three times a day for 2 weeks. All tablets are prepared by the Reyhan Naghsh Jahan Pharmaceutical Co., Isfahan, Iran. MAIN OUTCOMES: The main outcomes are changes in the coronavirus disease's clinical symptoms including duration and severity from baseline to the end of 2 weeks. RANDOMIZATION: Eligible patients will be randomly allocated in a 1:1 ratio to the intervention or control group. Randomization will be performed on the basis of permuted block sizes of 4 and will be stratified according to sex categories. Randomization sequences will be prepared by the trial's pharmacist with the use of random-number tables. BLINDING (MASKING): The trial-group assignment will be concealed from all participants, clinicians, and investigators throughout the trial. To ensure blinding, randomization sequences will be kept in identical, opaque, sealed, sequentially numbered envelopes. Only the trial's pharmacist has access to the randomization list. Also, the placebo tablet will be similar to the propolis tablet in terms of texture, taste, color, odor, and weight. Both tablets will be provided in containers that are completely identical in weight, shape, labelling, and packaging. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): The calculated total sample size is 80 patients, with 40 patients in each group. TRIAL STATUS: The protocol is Version 1.0, October 10, 2020. Recruitment began August 22, 2020, and is anticipated to be completed by March 21, 2021. TRIAL REGISTRATION: The name of the trial register: The effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19): A randomized, double-blind, placebo-controlled clinical trial. IRCT registration number: IRCT20200802048267N1 . Date of trial registration: 20 October 2020, retrospectively registered. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Miryan M, Soleimani D, Dehghani L, et al. The effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33272309. doi:10.1186/s13063-020-04934-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。